Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based pharmaceutical company Forest Laboratories has received the FDA approval of its supplemental new drug application for Lexapro for the acute and maintenance treatment of major depressive disorder in adolescents, 12-17 years of age.
Subscribe to our email newsletter
The approval of Lexapro for the treatment of adolescent depression was supported by two placebo-controlled studies, one conducted in adolescent patients taking Lexapro and one conducted in children and adolescents taking citalopram.
Lexapro is said to be the only second antidepressant to be approved for the treatment of major depressive disorder in adolescents.
Howard Solomon, chairman and CEO, of Forest Laboratories, said: “We have long believed that Lexapro would be of benefit for the treatment of depression in adolescents and that is why we undertook the several studies described in the package insert.
“We are enormously gratified that Lexapro will be available for depressed adolescents who so much require the benefits which Lexapro has made available for depressed adults for the past seven years.”